Tg Therapeutics's 15min chart triggers MACD Death Cross, Bollinger Bands Narrowing.

Based on my analysis of Tg Therapeutics's 15-minute chart, the MACD indicator has crossed below the signal line, indicating a potential continuation of the downward trend. Furthermore, the Bollinger Bands have narrowed, suggesting a decrease in the magnitude of price fluctuations. Therefore, the stock price is expected to continue falling, with a reduced likelihood of significant price swings.

uniQure (QURE) shares have experienced a significant surge, rallying 247.7% in the last trading session to close at $47.5 Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength?^[1]. This substantial increase can be attributed to the company's announcement that its investigational gene therapy, AMT-130, achieved primary and key secondary endpoints in a pivotal phase I/II study for Huntington’s disease. The high-dose treatment demonstrated significant slowing of disease progression by 75% on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) and 60% on Total Functional Capacity (TFC) at 36 months compared to a propensity score-matched external control. The stock's performance has been bolstered by robust data and investor optimism, with the company planning a regulatory filing in early 2026. Despite the recent gains, QURE is expected to post a quarterly loss of $0.87 per share, representing a year-over-year change of +4.4%. Revenues are projected to reach $6.93 million, up 202.8% from the year-ago quarter.

In contrast, TG Therapeutics (TGTX) finished the last trading session 0.5% lower at $35.41. The stock has returned 25.8% over the past month. The consensus EPS estimate for TGTX's upcoming report has changed -1.6% over the past month to $0.24, representing a +1100% change from the previous year. TGTX currently carries a Zacks Rank of #4 (Sell) Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength?^[1].

Analyzing the 15-minute chart of TG Therapeutics, the MACD indicator has crossed below the signal line, indicating a potential continuation of the downward trend. Additionally, the Bollinger Bands have narrowed, suggesting a decrease in the magnitude of price fluctuations. This technical analysis suggests that the stock price is expected to continue falling, with a reduced likelihood of significant price swings .

For investors, it is crucial to monitor earnings estimate revisions, as trends in these revisions are strongly correlated with near-term stock price movements. While uniQure's recent jump in stock price is notable, the absence of a trend in earnings estimate revisions should be watched closely to determine if this rally can turn into sustained strength. TG Therapeutics, on the other hand, shows a downward trend both in terms of price and earnings estimates, indicating a potential for continued decline.